Equibles does not estimate personal net worth.
Ben Taylor is recorded as CFO at Recursion Pharmaceuticals, Inc. (RXRX). The newest filing on record that lists Ben Taylor as CFO at Recursion Pharmaceuticals, Inc. (RXRX) is dated April 30, 2026. Recursion Pharmaceuticals, Inc. reported in an 8-K filed November 20, 2024 that Ben Taylor was appointed Chief Financial Officer of the Company and President of Recursion UK, effective November 20, 2024. The proxy statement of Recursion Pharmaceuticals, Inc. reports total compensation of $1,328,483 for Ben Taylor in fiscal 2025, including a base salary of $538,680. Disclosed compensation is on record for 2 fiscal years. Ben Taylor has spoken on 6 earnings calls and 3 other investor events across 1 company, most recently for Recursion Pharmaceuticals, Inc. on September 15, 2026. Recursion Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Recursion Pharmaceuticals, Inc. includes Christopher C. Gibson (CEO and Board Member), Najat Khan (CEO), Najat Khan, Ph.D. (CEO and Board Member) and 7 others.
“On November 20, 2024, the Board appointed Ben Taylor ("Mr. Taylor"), age 47, as Chief Financial Officer of the Company and President of Recursion UK, effective as of November 20, 2024.”
“So, as you mentioned earlier, we've brought in 525 million in upruns and milestones from our partnerships. We've hit over a dozen milestones. This was another key one because it was also advancing the biology side of the platform.”
“And first of all, thanks for having us here, Tommy. This is always a terrific conference and great to be here. So taking a step back, if you think about what recursion does as a whole, is we combine different ways of predicting models, whether it's biology, chemistry, or Clintec.”
“Well, at the heart of it, we're a therapeutics company. And so we really focus on making sure that we're advancing the pipeline and getting value drivers from that.”
“Our core focus from a financial perspective is ensuring we have adequate runway to achieve multiple upcoming milestones. We continued our trend of operating discipline with a 30% year-over-year reduction in cash operating expenses.”
“So 2025 was a year of financial transformation for the company. As a part of the integration, we decided to rebuild all of our corporate systems from the ground up.”
2024-11-20–present
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
CFO
2024-11-20–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Recursion Pharmaceuticals, Inc. (RXRX) | Chief Financial Officer | $538,680 | $1,328,483 |
| 2024 | Recursion Pharmaceuticals, Inc. (RXRX) | Chief Financial Officer | $53,392 | $8,171,651 |
